Published in Neurotherapeutics on July 01, 2008
The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol (2010) 3.32
5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo. Ann Neurol (2010) 2.06
The many substrates of presenilin/γ-secretase. J Alzheimers Dis (2011) 2.02
Genetics of Alzheimer's disease: recent advances. Genome Med (2009) 1.95
Recent developments in Alzheimer's disease therapeutics. BMC Med (2009) 1.63
An overview of APP processing enzymes and products. Neuromolecular Med (2010) 1.54
Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One (2009) 1.52
Golgi defects enhance APP amyloidogenic processing in Alzheimer's disease. Bioessays (2014) 1.48
γ-Secretase inhibitors and modulators. Biochim Biophys Acta (2013) 1.32
Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase. Am J Pathol (2011) 1.28
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? Biochim Biophys Acta (2010) 1.11
γ-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem (2011) 1.09
Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci (2010) 1.09
Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res (2010) 1.08
Toward structural elucidation of the gamma-secretase complex. Structure (2009) 1.07
Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. Proc Natl Acad Sci U S A (2012) 1.02
Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim Biophys Acta (2011) 1.02
Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother (2010) 0.99
Structural and mechanistic commonalities of amyloid-β and the prion protein. Prion (2011) 0.95
Bivalent ligands targeting multiple pathological factors involved in Alzheimer's disease. ACS Med Chem Lett (2012) 0.91
A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease. PLoS One (2013) 0.90
Human CRB2 inhibits gamma-secretase cleavage of amyloid precursor protein by binding to the presenilin complex. J Biol Chem (2010) 0.87
Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity. Neural Plast (2012) 0.86
Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J Neuroinflammation (2012) 0.85
Neuronal death in Alzheimer's disease and therapeutic opportunities. J Cell Mol Med (2009) 0.84
An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1. Biochemistry (2009) 0.84
Novel lipid signaling pathways in Alzheimer's disease pathogenesis. Biochem Pharmacol (2013) 0.83
Therapeutic potential of a gamma-secretase inhibitor for hearing restoration in a guinea pig model with noise-induced hearing loss. BMC Neurosci (2014) 0.83
Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol (2009) 0.83
Drug development for Alzheimer's disease: recent progress. Exp Neurobiol (2010) 0.82
Notch transcriptional control of vascular smooth muscle regulatory gene expression and function. J Biol Chem (2013) 0.82
Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. Yale J Biol Med (2016) 0.81
Novel strategies for the prevention of dementia from Alzheimer's disease. Dialogues Clin Neurosci (2009) 0.78
Effects of Folic Acid on Secretases Involved in Aβ Deposition in APP/PS1 Mice. Nutrients (2016) 0.78
Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence. Sci Rep (2015) 0.77
Amyloidosis in Retinal Neurodegenerative Diseases. Front Neurol (2016) 0.76
Heterogeneity in oligodendroglia: Is it relevant to mouse models and human disease? J Neurosci Res (2016) 0.76
GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome. Ann Neurol (2015) 0.75
Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins. J Cent Nerv Syst Dis (2011) 0.75
Degradation of gamma secretase activating protein by the ubiquitin-proteasome pathway. J Neurochem (2015) 0.75
The Components of Flemingia macrophylla Attenuate Amyloid β-Protein Accumulation by Regulating Amyloid β-Protein Metabolic Pathway. Evid Based Complement Alternat Med (2012) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature (1998) 10.58
A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 10.36
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 8.31
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature (1999) 8.28
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 7.43
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry (1993) 7.26
Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature (1995) 6.62
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 5.14
The role of presenilin cofactors in the gamma-secretase complex. Nature (2003) 5.03
Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature (2000) 4.68
Reconstitution of gamma-secretase activity. Nat Cell Biol (2003) 4.66
Nicastrin functions as a gamma-secretase-substrate receptor. Cell (2005) 4.64
Skeletal and CNS defects in Presenilin-1-deficient mice. Cell (1997) 4.50
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science (2002) 4.39
aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell (2002) 4.37
Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem (2004) 4.27
Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 4.12
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol (2004) 3.81
Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci (2003) 3.79
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A (2003) 3.36
Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature (1997) 3.14
Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol (2000) 2.84
Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol (2000) 2.53
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem (2003) 2.31
Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem (2003) 2.22
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology (2006) 2.21
Purification and characterization of the human gamma-secretase complex. Biochemistry (2004) 2.18
Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A (2002) 2.16
APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A (2002) 2.16
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat Cell Biol (2000) 1.92
The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med (1996) 1.86
Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem (2003) 1.83
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol (2007) 1.81
CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production. Proc Natl Acad Sci U S A (2005) 1.73
Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry (1999) 1.67
The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J Biol Chem (1998) 1.66
Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol (2005) 1.65
Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry (2004) 1.61
The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. Proc Natl Acad Sci U S A (2005) 1.59
Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem (2004) 1.51
Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci (1998) 1.50
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem (2005) 1.45
Secretion of the Notch-1 Abeta-like peptide during Notch signaling. J Biol Chem (2006) 1.44
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord (2007) 1.44
Different cofactor activities in gamma-secretase assembly: evidence for a nicastrin-Aph-1 subcomplex. J Cell Biol (2003) 1.38
Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1. J Biol Chem (2005) 1.36
Endoproteolytic processing and stabilization of wild-type and mutant presenilin. J Biol Chem (1997) 1.33
Designed helical peptides inhibit an intramembrane protease. J Am Chem Soc (2003) 1.33
Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther (2004) 1.32
Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther (2005) 1.32
Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Biochemistry (1999) 1.29
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther (2007) 1.29
Evidence that the "NF" motif in transmembrane domain 4 of presenilin 1 is critical for binding with PEN-2. J Biol Chem (2005) 1.28
The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther (2003) 1.24
Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol (2005) 1.20
Differential effects of inhibitors on the gamma-secretase complex. Mechanistic implications. J Biol Chem (2003) 1.15
Immature nicastrin stabilizes APH-1 independent of PEN-2 and presenilin: identification of nicastrin mutants that selectively interact with APH-1. J Neurochem (2004) 1.09
The transmembrane domain region of nicastrin mediates direct interactions with APH-1 and the gamma-secretase complex. J Biol Chem (2003) 1.00
Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem (2004) 0.93
The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry (2006) 1.70
Intramembrane-cleaving proteases. J Biol Chem (2009) 1.14